USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
09 Jun 2022 | 02:45 PM GMT

B2B2C Models for DTx products

Anchored by:

Eugene Borukhovich
Co-Founder & COO
YOURCOACH HEALTH

Participants:

Eugene Borukhovich Co-Founder & COOYourCoach Health
Eugene Borukhovich
Co-Founder & COOYourCoach Health
Ary Deleray Digital Health Business LeaderRoche
Ary Deleray
Digital Health Business LeaderRoche
Joseph Rubinsztain CEOChronWell
Joseph Rubinsztain
CEOChronWell
Karine Soulat Marketing Consultant on health and e healthKe-Health
Karine Soulat
Marketing Consultant on health and e healthKe-Health
Logan Smith Head of ProductHulaTech
Logan Smith
Head of ProductHulaTech
Marc Blanchard Founder & CEOATREON
Marc Blanchard
Founder & CEOATREON
Omri Shor CEOMedisafe
Omri Shor
CEOMedisafe
Ricardo C. Berrios Co-Founder & CEOAdhera Health, Inc.
Ricardo C. Berrios
Co-Founder & CEOAdhera Health, Inc.
Richie Bavasso PresidentPneumoWave
Richie Bavasso
PresidentPneumoWave
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Sarah Beeby CBOBlake Health
Sarah Beeby
CBOBlake Health

About this Meeting

Most digital therapeutics (DTx) companies opt to pursue B2B business models, such as partnerships with pharma, employers or payers. Ultimately, however, the end consumer will be the patient. This leads to complex models where DTx companies have to figure out how to be successful with a B2B approach while also excelling at activating and engaging consumers.  

At this meeting, we will look at how DTx companies can approach getting the right B2B2C business model and how to tailor the approach to the product and the market. More specifically we will discuss: 

  • What are the most scalable and sustainable B2B models for DTx companies (partnerships with pharma, employers, payers, etc)? 
  • How to make the B2B part work? What metrics can we use to understand the success of the model? 
  • B2C marketing and communication strategies: what are the best practices to activate patients with the DTx solution? Post-launch how can people engage to complete the treatment? Who is responsible for doing this in a B2B2C model? 
  • No one size fits all approach: How can companies test different B2B2C models at the same time? How can companies structure themselves to manage the implications of having more than one concurrent model to tackle, potentially in parallel?